Gabriel Carrasquilla

Prof. Gabriel Carrasquilla

ASIESALUD
orcid

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2009 in Salud Pública de México
Verified
Journal Article
Open access
PDF file
VCVelásquez-De Charry
Velásquez-De Charry
LCLigia Constanza
Ligia Constanza
GCGabriel Carrasquilla
Gabriel Carrasquilla
SRSandra Roca-Garavito
Sandra Roca-Garavito
To evaluate equity in access by comparing geographic, economic, and organizational barriers as well as authorization obstacles that women encounter depending on their affiliation with the social security health system. A retrospective survey was conducted among women undergoing breast cancer treatment to determine differences and the degree of fairness in access to care according to their affiliation with the social security health system. Women affiliated with the subsidized social security health system as well as women living in rural areas have a greater probability to travel to another city (OR 2.40 IC95%;1.64-3.43 and OR 1.80 IC95%;1.04-3.06, respectively). Poor women without insurance have greater probability of having to pay for medications (OR 3.7 IC95%;2.15-6.44). Access to breast cancer treatment is inequitable and particularly detrimental to vulnerable populations.

1 January 2012 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Closed access
GCGabriel Carrasquilla
Gabriel Carrasquilla
CBClemencia Barón
Clemencia Barón
EMEdwin M. Monsell
Edwin M. Monsell
MCMarc Cousin
Marc Cousin
VWVerena Walter
Verena Walter
LFLaurel M. Fisher
Laurel M. Fisher
The safety of artemether-lumefantrine in patients with acute, uncomplicated Plasmodium falciparum malaria was investigated prospectively using the auditory brainstem response (ABR) and pure-tone thresholds. Secondary outcomes included polymerase chain reaction-corrected cure rates. Patients were randomly assigned in a 3:1:1 ratio to either artemether-lumefantrine (N = 159), atovaquone-proguanil (N = 53), or artesunate-mefloquine (N = 53). The null hypothesis (primary outcome), claiming that the percentage of patients with a baseline to Day-7 ABR Wave III latency increase of > 0.30 msec is ≥ 15% after administration of artemether-lumefantrine, was rejected; 2.6% of patients (95% confidence interval: 0.7–6.6) exceeded 0.30 msec, i.e., significantly below 15% (P < 0.0001). A model-based analysis found no apparent relationship between drug exposure and ABR change. In all three groups, average improvements (2–4 dB) in pure-tone thresholds were observed, and polymerase chain reaction-corrected cure rates were > 95% to Day 42. The results support the continued safe and efficacious use of artemether-lumefantrine in uncomplicated falciparum malaria.

1 October 2020 in Vaccine
Verified
Journal Article
Open access
GCGabriel Carrasquilla
Gabriel Carrasquilla
APAlexandra Porras-Ramirez
Alexandra Porras-Ramirez
SMSandra Martinez
Sandra Martinez
RDRodrigo DeAntonio
Rodrigo DeAntonio
RDRaghavendra Devadiga
Raghavendra Devadiga
PJPatricia Juliao
Patricia Juliao
Maternal immunization with tetanus, diphtheria, and acellular pertussis (Tdap) vaccine confers protection to young infants. We aimed to describe trends in pertussis incidence and associated mortality in children aged <12 months before and after introduction of maternal Tdap immunization in Bogotá, Colombia. Data on pertussis-related cases/deaths in infants aged <12 months were collected from SIVIGILA for the period 2005-2016, and compared incidence for the pre-vaccine introduction (2005-2012) and post-maternal Tdap vaccination (2014-2016) periods in infants aged <12 months and in three distinct age-strata; ≤6 weeks, 7-<28 weeks, and 28-52 weeks. Mortality comparisons were performed in all infants <12 months. From 2005 to 2016, 2315 laboratory or clinically-confirmed pertussis cases were reported in infants <12 months of age (278 cases in young infants aged ≤6 weeks); 55 pertussis deaths were reported in children aged <12 months. No pertussis deaths were reported in the 2014-2016 period. Since maternal Tdap introduction in 2013, a consistent decline in pertussis incidence and mortality was observed. In the time-series analysis, incidence declined from 209.4/100,000 persons (2005-2012) to 49.1/100,000 persons (2014-2016) in all children <12 months; a 87.5% (95%CI: 77.2-93.2%) reduction. For these same period's incidence in young infants ≤6 weeks declined from 196.7 to 89.6/100,000 person-years (an 54.4% [95% CI: 35.4-67.9%] reduction). Greater incidence reductions were observed in older infants; 73.4% (95% CI: 68.4-77.6%) in those aged 7-<28 weeks, and 100% in those aged 28-52 weeks. A 100% reduction in Pertussis mortality in infants <12 months was observed. Since Tdap introduction, maternal vaccine coverage rose from <60% in 2013-2015 to 80% in 2016. Implementation of maternal immunization in Bogotá may have contributed to the reduction in pertussis incidence and mortality among infants <12 months of age (ClinicalTrials.gov: NCT02569879). An Audio Summary linked to this article that can be found on Figshare https://doi.org/10.6084/m9.figshare.12943316.

29 May 2014 in Malaria Journal
Verified
Journal Article
Open access
PDF file
APAlexandra Porras-Ramirez
Alexandra Porras-Ramirez
JBJosé Israel Galindo Buitrago
José Israel Galindo Buitrago
JGJuan P Pimentel González
Juan P Pimentel González
AMAndres Herrera Moráles
Andres Herrera Moráles
GCGabriel Carrasquilla
Gabriel Carrasquilla
Malaria is a serious health problem in Colombia. This paper intends to analyse the frequency and tendencies of the disease in Colombia over the last 22 years. The researchers used the Box-Jenkins (ARIMA) methodology for the analysis of time series.

10 July 2007 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Closed access
PDF file
FCFrancia Ivonne Campos
Francia Ivonne Campos
CKChihaya Koriyama
Chihaya Koriyama
SASuminori Akiba
Suminori Akiba
GCGabriel Carrasquilla
Gabriel Carrasquilla
MSMauricio Serra
Mauricio Serra
ANAtsuhiro Nakano
Atsuhiro Nakano

18 August 2017 in Pathogens and Global Health
Verified
Journal Article
Closed access
JQJuliana Quintero-Espinosa
Juliana Quintero-Espinosa
TGTatiana García-Betancourt
Tatiana García-Betancourt
ACANDREA CAPRARA
ANDREA CAPRARA
CBCesar Basso
Cesar Basso
ERElsa Garcia da Rosa
Elsa Garcia da Rosa
AKAxel Kroeger
Axel Kroeger
Prior to the current public health emergency following the emergence of chikungunya and Zika Virus Disease in the Americas during 2014 and 2015, multi-country research investigated between 2011 and 2013 the efficacy of novel Aedes aegypti intervention packages through cluster randomised controlled trials in four Latin-American cities: Fortaleza (Brazil); Girardot (Colombia), Acapulco (Mexico) and Salto (Uruguay). Results from the trials led to a scaling up effort of the interventions at city levels. Scaling up refers to deliberate efforts to increase the impact of successfully tested health interventions to benefit more people and foster policy and program development in a sustainable way. The different scenarios represent examples for a ‘vertical approach’ and a ‘horizontal approach’. This paper presents the analysis of a preliminary process evaluation of the scaling up efforts in the mentioned cites, with a focus on challenges and enabling factors encountered by the research teams, analysing the main social, political, administrative, financial and acceptance factors.